Eli Lilly filed six federal lawsuits on August 12, 2026 against US companies it accuses of selling black-market versions of retatrutide, the triple agonist it still has in Phase 3 trials. Four of the six cases were filed in Texas. The named defendants are a mix of peptide sellers, a compounding pharmacy and a medical spa — and the shape of that list is the story, because it is the first time Lilly has taken the research-supply channel to court by name rather than referring it to regulators.
Alongside the filings, Lilly published an open call to online platforms, credit card companies, payment processors and shipping carriers to cut off the sellers' infrastructure. For anyone who follows peptide supply, that second half is the more consequential document. Litigation moves in years; a processor decision moves in a week.
Research-context information only. This article reports on newly filed civil complaints and a company press release as published. A complaint is an allegation, not a finding, and none of these cases has been decided on the merits. Nothing here is medical or legal advice. Retatrutide is an investigational molecule in Phase 3 clinical trials and is not approved for any use in humans in any country; research-use-only material sold by peptide vendors is not FDA-approved for human use and has not been evaluated for safety, purity or potency as sold. Consult a licensed physician for personal medical decisions.
Update 2026-10-10
Lilly dropped the Aesthetic Envy case. On September 11, 2026, Lilly filed a notice of voluntary dismissal under Federal Rule of Civil Procedure 41(a)(1)(A)(i), and on September 14 the court entered the dismissal with prejudice and closed the case (Eli Lilly and Co. v. Aesthetic Envy Cosmetic Centers LLC, No. 2:26-cv-02764, E.D. Cal.). A waiver of service had been filed on August 19, and no answer had been filed. The public docket does not say why Lilly dismissed or whether any settlement terms were agreed, so we draw no conclusion beyond the dismissal itself.
Court correction. Lilly's August 12 release listed this case in the Northern District of California, and our original version repeated that. The docket shows it was filed in the Eastern District of California; the court is corrected throughout this article. The docket numbers for all six cases are now in the table below.
Astra: one defendant dropped, the case continues. Some coverage describes the Astra suit as dismissed. The docket does not support that. On August 31 Lilly filed a First Amended Complaint that kept Astra LLC d/b/a Astra Peptides and added a second defendant, "Astra Peptides, an entity or person doing business under that assumed or common name whose true legal identity is presently unknown." On September 2 Lilly filed a notice of voluntary dismissal, and the docket lists Astra LLC as terminated from the case that day. The case itself stayed open: on September 30 Lilly moved for pre-service discovery to determine the remaining defendant's identity, and on October 1 Judge Fred Biery entered a court advisory on discovery that still carries both names in the caption (Eli Lilly and Co. v. Astra LLC, No. 5:26-cv-05147, W.D. Tex.). The notice itself is not in the public archive, so whether the dismissal of Astra LLC was with or without prejudice, or tied to any agreement, is not visible.
Legendary Peptides has moved to dismiss. After an agreed extension of its answer deadline to October 2, Legendary Peptides filed a motion to dismiss under Rules 12(b)(1) and 12(b)(6) on that date (No. 1:26-cv-00347, E.D. Tex.). The motion argues that Lilly lacks Article III standing, calling its theory of diverted sales speculative and its harm to a not-yet-approved product neither actual nor imminent. It argues that Lilly lacks statutory standing for its eight state-law claims, and that Texas common law does not recognise an unfair-competition claim built on a violation of the Texas Food, Drug, and Cosmetic Act. Under a September 10 order, Lilly has 44 days after service to respond. These are the defendant's arguments; the court has not ruled.
Striker Pharmacy has appeared. Striker waived service, with its answer due October 20. Its counsel appeared on October 1, and on October 3 it filed an unopposed motion for more time to respond to the complaint. The parties filed a joint discovery and case management plan, and Judge Kenneth M. Hoyt held a scheduling conference on October 5 (No. 4:26-cv-06563, S.D. Tex.).
Texas Peptides and Lone Star Peptide: no appearance on the available docket. Texas Peptides was served on August 17, with an answer due September 8. The case was reassigned to Judge Micaela Alvarez on August 31, and a September 2 order set a joint discovery plan deadline of November 2 (No. 5:26-cv-05146, W.D. Tex.). Lilly filed a certificate of service in the Lone Star case on August 20, and on September 11 it moved to strike or excuse compliance with a discovery-planning deadline (No. 4:26-cv-06562, S.D. Tex.). Neither docket, as archived on CourtListener, shows an appearance or answer by the defendant. Public docket copies can lag the court's own record, so the absence of an entry is not proof that nothing was filed.
Five more suits filed October 8
Lilly filed five more retatrutide complaints on Thursday, October 8, 2026, Bloomberg Law reported. The dockets show the new cases spread the campaign beyond Texas and California into Louisiana and Arizona:
| Case | Court |
|---|---|
| Eli Lilly & Co. v. American Peptides L.L.C. | W.D. La., No. 5:26-cv-04146 |
| Eli Lilly and Co. v. Cenexa Labs LLC | S.D. Tex., No. 4:26-cv-08806 |
| Eli Lilly and Co. v. MedShape Weight Loss Clinic LLC | D. Ariz., No. 2:26-cv-07361 |
| Eli Lilly and Co. v. Brown (William "Ian" Brown, d/b/a LiveWell Peptides) | N.D. Tex., No. 3:26-cv-03514 |
| Eli Lilly and Co. v. Southlake Mhya PLLC | N.D. Tex., No. 4:26-cv-01294 |
Bloomberg Law's defendant list names "Medrein Health & Aesthetics" where the fifth docket caption reads Southlake Mhya PLLC. That complaint is not yet public, so we report the caption as filed.
Of the five complaints, only the LiveWell filing is publicly available so far, and it follows the August template almost word for word. It describes LiveWell as a Dallas-based online seller of purportedly "research use only" products. It alleges the company markets products it claims contain retatrutide for human use, and it pleads eight state-law unfair-competition and unfair-trade-practice claims (Alaska, Colorado, Connecticut, North Carolina, South Carolina, Tennessee, Texas common law and Washington). Lilly asks for a permanent injunction barring the sale of any product containing or purporting to contain retatrutide, plus damages, disgorgement of profits and attorneys' fees. The complaint also states that the FDA "has issued at least 21 warning letters to sellers of illegal retatrutide products" in recent months.
Three things changed with this round. The defendant list now reaches outside the two states where the August cases sit. One suit names an individual doing business under a trade name rather than a company. And the mix again pairs research-supply sellers with weight-loss and aesthetics clinics. As with the August group, these are allegations in complaints, none of the five is a vendor we list or track, and none of the defendants had responded on the docket as of October 9.
Update 2026-08-14
Three of the six defendants have already pulled their retatrutide listings. CBS News reported on the day the suits were filed that Lone Star Peptide, Texas Peptides and Aesthetic Envy all took down their webpages advertising retatrutide, and that Legendary Peptides had no immediate comment while the remaining defendants did not respond to requests for comment. None of the six has announced a closure, and taking a listing down is not an admission of anything — but it does confirm the pattern noted below: the response to this kind of pressure shows up as catalog and checkout changes within days, long before anything happens on a docket.
The six cases
Lilly filed each suit separately rather than as a single consolidated action, which spreads them across four federal districts:
| Case | Court |
|---|---|
| Eli Lilly & Co. v. Aesthetic Envy Cosmetic Centers LLC | E.D. Cal., No. 2:26-cv-02764 (voluntarily dismissed with prejudice, September 14, 2026) |
| Eli Lilly & Co. v. Astra LLC | W.D. Tex., No. 5:26-cv-05147 (Astra LLC terminated as a party September 2, 2026; case continues against an unidentified "Astra Peptides" defendant) |
| Eli Lilly & Co. v. Legendary Peptides, LLC | E.D. Tex., No. 1:26-cv-00347 |
| Eli Lilly & Co. v. Striker Pharmacy, LLC | S.D. Tex., No. 4:26-cv-06563 |
| Eli Lilly & Co. v. Texas Peptides Inc. | W.D. Tex., No. 5:26-cv-05146 |
| Eli Lilly & Co. v. Lone Star Peptide Co. | S.D. Tex., No. 4:26-cv-06562 |
Lilly's stated theory across the group is that the defendants marketed retatrutide products to consumers for weight loss while the molecule remains investigational, and that some of them labelled the material "research use only" while intending and understanding it to be used by humans. The company also says product in this channel is frequently sourced from unregulated foreign manufacturers. David A. Hyman, M.D., Lilly's chief medical officer, put the company's position in one line: "What is being sold on the black market is not a medicine – it is entirely unverified, unapproved and not worth the risk."
Those are Lilly's characterisations, made in complaints it has an obvious commercial interest in bringing. No defendant had answered as of publication, and none of the six had announced a closure.
The filings are the visible tip of a much larger private enforcement operation. Lilly says it has reported more than 14,000 websites, advertisements, social media posts and product listings marketing retatrutide across more than 100 countries to internet service providers, social platforms and e-commerce companies, and has referred more than 200 individuals and entities to the FDA, the Department of Justice, state attorneys general, law enforcement and professional licensing boards. Six lawsuits against a 14,000-listing problem is not an attempt at coverage. It is an attempt at precedent.
The ask that actually moves supply
The lawsuits will take years. The press release will not.
In the same announcement, Lilly asked four groups to act without waiting for a court: regulators and law enforcement to prioritise cross-border enforcement, social media and e-commerce platforms to proactively block listings, credit card companies, payment processors and shipping carriers to cut off transaction infrastructure, and healthcare providers to raise awareness with patients.
The third of those is the one to watch. On our own tracking of the past two years, payment processing has been the most reliable predictor of whether a peptide vendor stays in business — not FDA letters, not litigation, not state pharmacy rules. Vendors that lost a processor disappeared within weeks; vendors that kept one absorbed regulatory pressure and continued trading. Our record of which vendors shut down across 2025 and 2026 is, read closely, mostly a record of banking relationships ending. The same dynamic surfaced in the compounding world's own litigation: Strive's antitrust complaint against Lilly and Novo Nordisk alleged processor interference as one of three chokepoints, and that case was dismissed on August 3 without the processor theory ever being tested.
What that means practically is that the near-term signal is not a docket entry. It is checkout friction — cards declining, a vendor switching processors, crypto or ACH appearing as the only option, or shipping delays on inbound stock. Those changes show up in weeks, and they show up per-vendor rather than across the market at once.
What changes for buyers, and what does not
Three things are worth separating, because reporting on this story has run them together.
The suits are against six named entities, not the channel. None of the six defendants is a vendor we list or track. Nothing in the filings names, binds or restrains any other seller, and no court has ordered anything yet. Our comparison surfaces are unchanged by the litigation itself, and current per-milligram pricing, coupon status and COA availability are live on the retatrutide buying surface.
Retatrutide's legal status did not change on August 12 — it was already investigational. The compound has no approval anywhere in the world. Reporting on the cases notes the FDA's existing position that sales of unapproved retatrutide to consumers are unlawful and that the molecule cannot lawfully be compounded, which is why the PCAC 503A peptide vote in late July covered BPC-157, KPV, TB-500, MOTS-c, epitalon and semax and no GLP-1-class compound. Our legality guide sets out the research-use-only distinction in full.
Concentration of risk is the real variable. A market served by six large sellers is fragile in a way that a market served by thirty is not. What this campaign is designed to do — flag listings, pressure processors, refer entities to licensing boards — raises the operating cost of every seller at once, and the vendors with the thinnest margins and the most improvised payment arrangements feel it first. For a buyer, that argues for tracking who currently holds stock, price and a published COA rather than assuming last quarter's answer still holds.
